The present invention is related to ophthalmic formulations for the treatment of ocular ailments. More specifically it is related to the pharmaceutical industry in the production of ophthalmic medication for the treatment of ocular hypertension. The advantage of the present invention over other state of the art treatments is that it achieves a composition of Dorzolamide Hydrochloride Timolol Maleate and Brimonidine Tartrate with excellent properties of stability; it does not give rise to chemica...

PROBLEM TO BE SOLVED: To provide a pharmaceutical formulation orally administrable of one or a plurality of active pharmaceutical ingredients (API) for providing quick oral intake. SOLUTION: There are provided a pharmaceutical formulation containing one or a plurality of APIs suitable for oral intake and cacao powder a method for producing the formulation and use of the formulation for therapy. As the APIs eletriptan terbutaline sulfate triazolam maleic acid chlorophenylamine dextropropoxyphene...

The present invention provides a process for preparing optically active timolol. The process comprises the following steps. Firstly, reacting 3-hydroxy-4-morpholino-1,2,5-thiadiazole with an optically active epichlorohydrin in the presence of a solvent system, which has a first volume and a catalyst optionally in the presence of a suitable base to obtain an optically active intermediate product. Secondly, treating the optically active intermediate product with a solution, which has a second volu...

New compositions for and methods of treating ocular hypertension provide for effective treatment of ocular hypertension often using reduced concentrations of active components. Such compositions include a timolol component and a hypotensive lipid component. The present compositions and methods are relatively straightforward can be easily produced for example using conventional manufacturing techniques and can be easily and conveniently practiced for example using application or administration te...

The present invention is related to ophthalmic composition comprising Timolol Dorzolamide and Brimonidine. More specifically the present invention is related to a stable ophthalmic composition comprising Timolol Dorzolamide and Brimonidine and hydroxyethyl cellulose.

The present invention is related to ophthalmic composition comprising Timolol, Dorzolamide and Brimonidine. More specifically, the present invention is related to a stable ophthalmic composition comprising Timolol, Dorzolamide and Brimonidine and hydroxyethyl cellulose.

Disclosed is a water-based composition for eye drop which comprises a ss-blocker typified by timolol or carteolol or an a-blocker such as bunazosin together with boric acid or a pharmaceutically acceptable salt thereof but contains no preservative. It is unnecessary to add a preservative, which is used in the existing eye drops, to the aforesaid composition. Thus, it is expected that the composition exerts little effect on eye tissues even in prolonged use. Moreover, the eye drop is free from mi...